#insurance

11 articles tagged #insurance.

#2026 3#503a 1#503b 2#FDA 1#alternatives 1#ban 1#before-and-after 1#beginners 2#brand-name 3#bridge-program 2#comparison 2#compounded 7#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 12#countdown 1#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 1#fda 3#fda-approval 1#flat-rate 1#foundayo 6#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 5#injection 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 6#mounjaro 5#news 3#novo-nordisk 1#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 5#pill 1#policy 1#prior-authorization 1#regulation 2#results 1#rfk 1#ro 1#safety 3#savings-card 1#schedule 1#semaglutide 16#shortage 1#side-effects 9#supplements 1#surmount 2#telehealth-review 1#timeline 1#tirzepatide 17#wegovy 15#wegovy-pill 3#weight-loss 24#without-insurance 1#zepbound 17
Editorial still-life illustrating the Medicare GLP-1 Bridge enrollment process and access to weight-loss medication
GuideCost & InsuranceMay 19, 2026• 16 min read

Medicare GLP-1 Bridge Enrollment Guide 2026: $50 Copay for Foundayo, Wegovy & Zepbound

Updated May 19, 2026: The BALANCE Model Part D pilot was canceled April 21, 2026 — the Medicare GLP-1 Bridge is now the ONLY federal Medicare obesity pathway through December 31, 2027. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. The $50 does NOT count toward the Part D deductible or the $2,100 out-of-pocket cap. Prior auth routes to Humana (the CMS-designated central processor, operating via LI NET infrastructure). Eligible plan types: PDP, MA-PD, SNP, EGWP, and LI NET. Complete enrollment guide.

Editorial photograph illustrating a comparison of Zepbound and Mounjaro tirzepatide medications
AnalysisComparisonsApril 22, 2026• 12 min read

Zepbound vs Mounjaro (April 2026): Same Drug, Different Labels — Which Is Right for You?

Verified April 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo — a program Mounjaro does not offer.

Editorial lifestyle photograph illustrating a 2026 GLP-1 cost guide
AnalysisCost & InsuranceApril 17, 2026• 11 min read

GLP-1 Cost 2026: Wegovy, Zepbound & Ozempic Prices ($25–$1,350/mo)

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25–$1,350/month. With insurance + savings card: $25/mo. Without insurance: $115/mo compounded sema (Enhance MD), $149/mo Foundayo pill, $299–449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo starting July 2026. Prices verified April 17, 2026 across 48 providers.

Top Picks

Four programs our readers click through most.

Eden Health GLP-1

8.9/10
$249/mo·Brand & Compounded
Visit Eden Health GLP-1Review

Embody

7.3/10
$299/mo·Compounded
Visit EmbodyReview

Gala

7.2/10
$149/mo·Brand & Compounded
Visit GalaReview

Affiliate links — we earn a commission at no extra cost to you. Selection reflects what readers convert through, not editorial endorsement. Full ranking + methodology at glp1picks.com.

Top 3 Picks

Eden Health GLP-1$249/moVisit
Embody$299/moVisit
Gala$149/moVisit
or compare all 48 →